Report : Asia Pacific Histopathology Services Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type of Examination (Surgical Specimen, Breast Biopsy, Lung Biopsy, Renal Biopsy, Gastrointestinal Biopsy, Pancreatic Biopsy, Skin Tissue Biopsy, Testicular Biopsy, and Others) and End User (Diagnostic Laboratories & Reference Laboratories, Research Institutes, and Others)
The surgical specimen segment by type of examination is estimated to lead the market growth during the forecast period.
According to a new market research study of “Asia Pacific Histopathology Services Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type of Examination, End User and Country.” The Asia Pacific histopathology services market is expected to reach US$ 8,075.62 million in 2028 from US$ 5,289.34 million in 2021; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific histopathology services market and the factors driving market along with those that act as hindrances.
Countries such as India and China have large population suffering from chronic diseases. Thus, emerging markets in Asia-Pacific countries are creating significant opportunities for the business expansion of key histopathology services market players. Advancements in biotechnology have been encouraging the introduction of modern pathological systems that can be used in infectious disease testing, molecular oncology studies, and pharmacogenomics in emerging countries. Healthcare providers may target patients or consumers from various developing countries for studying diagnostic and histopathological tests. Further, the rising prevalence of various infectious diseases in these countries is likely to contribute to the growth of this market during the forecast period. Increasing research activities to develop effective treatments for chronic diseases are positively affecting the market growth. Researchers and therapists exploring therapies for these diseases conduct detailed histopathological analyses to understand the disease mechanisms, which assist in the designing of therapies for their management.
Countries in Asia Pacific are facing huge challenge due to continuous surge in COVID-19 cases. The disease outbreak has affected on diagnostic kits and drugs manufacturing, supply chains and distribution activities across the Asia Pacific region. This has hampered the performances of industries such as cancer diagnostics. Globally, histopathology and cytology workload reduced substantially which has hampered the market in the review period. Hence, a rapid increase in the number of infected patients in countries of Asia Pacific is likely to hamper the growth of histopathology services market.
The Asia Pacific histopathology services market, by type of examination, is segmented into surgical specimen, breast biopsy, lung biopsy, renal biopsy, gastrointestinal biopsy, pancreatic biopsy, skin tissue biopsy, testicular biopsy, and others. Based on end user, the Asia Pacific histopathology services market is segmented into diagnostic laboratories and reference laboratories, research institutes, and others. Geographically, the Asia Pacific histopathology services market can be sub-segmented into India, China, Japan, South Korea and Rest of Asia Pacific.
Sonic Healthcare Limited, TPL Path Labs, Targos, Cureline Global Translational CRO and CHARLES RIVER LABORATORIES, INC. are among the leading companies operating in the Asia Pacific histopathology services market.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com